Email this article 
Hide
Show all
Serum Level of Soluble Receptor for Advanced Glycation End Products in Acute Coronary Syndrome and Chronic Stable Angina Patients
Abstract
Acute coronary syndrome (ACS) and chronic stable angina (CSA) have different pathophysiological features and prognoses. Hence, a biomarker that can discriminate between ACS and CSA is crucial. Soluble receptor for advanced glycation end product (sRAGE) involved in vascular inflammation shows potential as the emerging diagnostic marker of ACS. Thus, this research examined the difference in serum level of sRAGE in ACS and CSA patients and investigated the association between sRAGE and plaque instability biomarkers like placental growth factor (PIGF). The serum levels of sRAGE and plaque instability biomarkers were measured from 13 ACS [47 years (26)] and 19 CSA patients [51 years (26)] using enzyme-linked immunoassay. The association between serum level of sRAGE and plaque instability biomarkers was determined by a correlation study. Serum level of sRAGE and PIGF were significantly higher in ACS [sRAGE: 3541 pg/mL (2153.8 pg/mL), p<0.000], [PIGF: 51.91 (31.94) pg/mL, p=0.001] compared to CSA patients [sRAGE: 1268 (1510) pg/mL], [PIGF: 17.28 (22.41) pg/mL]. Binomial logistic regression analysis revealed sRAGE and PIGF as possible predictors of ACS, p<0.05. The serum level of sRAGE was higher in ACS patients and could be the potential dual-biomarker with PIGF in cardiovascular disease (CVD) patients.
Keywords
Full Text:
PDFReferences
Agewall S. Acute and stable coronary heart disease: different risk factors. Eur Heart J. 2008 Jul 10;29(16):1927–9.
WHO. Cardiovascular disease. 2018.
Seong AC, Chb MB, Kok C, John M, Cth F. A Review of Coronary Artery Disease Research in Malaysia. 2016;71:42–57.
Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part III: Biomarkers of oxidative stress and angiogenic growth factors. Circulation. 2006;113(8):289–92.
Jensen LJN, Flyvbjerg A, Bjerre M. Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome. Biomed Res Int. 2015;2015.
Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, et al. Ratio of serum levels of ages to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015;
Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6(1):7–14.
Villegas-Rodríguez ME, Uribarri J, Solorio-Meza SE, Fajardo-Araujo ME, Cai W, Torres-Graciano S, et al. The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients. PLoS One. 2016;11(7).
Assiri AMA, Kamel HFM, ALrefai AA. Critical Appraisal of Advanced Glycation End Products ( AGEs ) and Circulating Soluble Receptors for Advanced Glycation End Products ( sRAGE ) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Med Sci. 2018;6(38):1–13.
Brinkley TE, Leng X, Nicklas BJ, Kritchevsky SB, Ding J, Kitzman DW, et al. Racial Differences in Circulating Levels of the Soluble Receptor for Advanced Glycation Endproducts in Middle-Aged and Older Adults Tina. Metabolism. 2017;70:98–106.
Grauen H, Yndigegn T, Marinkovic G, Grufman H, Mares R, Nilsson J, et al. The soluble receptor for advanced glycation end-products ( sRAGE ) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. Atherosclerosis. 2019;287:16–23.
Mahajan N, Dhawan V. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases. Int J Cardiol. 2013;168(3):1788–94.
Cai XY, Lu L, Wang YN, Jin C, Zhang RY, Zhang Q, et al. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis. 2011;217(2):536–42.
Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25(5):1032–7.
Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. 2009;205(2):544–8.
Loomis SJ, Chen Y, Sacks DB, Christenson ES, Robert H, Rebholz CM, et al. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community- Based Cohort Stephanie. Clin Chem. 2017;63(5):980–9.
Reichert S, Triebert U, Navarrete A, Hofmann B, Schaller H, Schlitt A, et al. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9.
Boudoulas KD, Triposciadis F, Geleris P, Boudoulas H. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Prog Cardiovasc Dis. 2016;58(6):676–92.
Basta, G., Turco, S.D., Marchi, F., Navarra, T., Battaglia, D., Mercuri, A., Mazzone A. & Berti S. Elevated soluble receptor for advanced glycation end product levels in patient with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis. 2011;
Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716–27.
Zheng H, Li Y, Xie N, Huang JL, Xu HF, Luo M. Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients. Genet Mol Res. 2015;14(2):3775–83.
Bower JK, Pankow JS, Lazo M, Christenson E, Hoogeveen RC, Ballantyne CM, et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem. 2014;47(1–2):132–4.
Falcone C, Bozzini S, Guasti L, D’Angelo A, Capettini AC, Paganini EM, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. ScientificWorldJournal. 2013;2013:584504.
Mulrennan S, Baltic S, Aggarwal S, Wood J, Miranda A, Frost F, et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931.
Geroldi D, Falcone C, Emanuele E, Angelo AD, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. 2005;1725–9.
Yoon S, Park S, Park C, Chang W, Cho D, Ko Y, et al. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Pahophysiology Nat Hist. 2012;23:85–90.
Fong SW, Few LL, See Too WC, Khoo BY, Nik Ibrahim NNI, Yahaya SA, et al. Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC Res Notes. 2015;8:679.
Wannamethee SG, Welsh P, Papacosta O, Ellins EA, Halcox JPJ, Whincup PH, et al. Circulating soluble receptor for advanced glycation end product : Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis. 2017;264:36–43.
Prasad K. Low Levels of Serum Soluble Receptors for AGEs, biomarkers for disease state, myth or reality. Int J Angiol. 2014;23(1):11–16.
Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, et al. Elevated Placental Growth Factor Levels Are Associated With Adverse Outcomes at Four-Year Follow-Up in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2006;47(2):307–11.
Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic Value of Placental Growth Factor in Patients With Acute Chest Pain. JAMA. 2004 Jan 28;291(4):435–41.
Lindahl B. Are there really biomarkers of vulnerable plaque? Clin Chem. 2012;58(1):151–3.
Ramachandra CJA, Ja KPMM, Chua J, Cong S, Shim W, Hausenloy DJ. Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxidants Redox Signal. 2020;32(15):1135–49.
Govindarajan S, Raghavan VMM, Rao ACV. Plasma myeloperoxidase and total sialic acid as prognostic indicators in acute coronary syndrome. J Clin Diagnostic Res. 2016;10(8):BC09-BC13.
Liu C, Xie G, Huang W, Yang Y, Li P, Tu Z. Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and high LDL-C levels in CHD patients. J Atheroscler Thromb. 2012;19(5):435–43.
Pusuroglu H, Akgul O, Erturk M, Uyarel H, Bulut U, Akkaya E, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis. 2014;25(7):558–64.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res. 2007;121(3):293–9.
Gremmel T, Frelinger AL, Michelson AD. Soluble CD40 ligand in aspirin-treated patients undergoing cardiac catheterization. PLoS One. 2015;10(8):1–16.
Mehta R, Bassand J, Chrolavicius S, Diaz R, Eikelboom JW, Health H, et al. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N Engl J Med. 2010;363(16):1585–1585.
Rondina MT, Lappe JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, et al. Soluble CD40 Ligand as a Predictor of Coronary Artery Disease and Long-Term Clinical Outcomes in Stable Patients Undergoing Coronary Angiography. Cardiology. 2008;109(3):196–201.
Copyright (c) 2021 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.